Last reviewed · How we verify
ranibizumab intravitreal injection
ranibizumab intravitreal injection is a anti-VEGF agent Small molecule drug developed by Hawaii Pacific Health. It is currently in Phase 3 development for Treatment of neovascular (wet) age-related macular degeneration, Treatment of macular edema following retinal vein occlusion.
Ranibizumab works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.
Ranibizumab works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis. Used for Treatment of neovascular (wet) age-related macular degeneration, Treatment of macular edema following retinal vein occlusion.
At a glance
| Generic name | ranibizumab intravitreal injection |
|---|---|
| Sponsor | Hawaii Pacific Health |
| Drug class | anti-VEGF agent |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
This mechanism of action is thought to reduce the formation of new blood vessels in the retina, which can contribute to conditions such as age-related macular degeneration. By inhibiting angiogenesis, ranibizumab can help slow disease progression and improve vision outcomes.
Approved indications
- Treatment of neovascular (wet) age-related macular degeneration
- Treatment of macular edema following retinal vein occlusion
Common side effects
- Intraocular inflammation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (PHASE4)
- A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (PHASE3)
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (PHASE3)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PHASE3)
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ranibizumab intravitreal injection CI brief — competitive landscape report
- ranibizumab intravitreal injection updates RSS · CI watch RSS
- Hawaii Pacific Health portfolio CI
Frequently asked questions about ranibizumab intravitreal injection
What is ranibizumab intravitreal injection?
How does ranibizumab intravitreal injection work?
What is ranibizumab intravitreal injection used for?
Who makes ranibizumab intravitreal injection?
What drug class is ranibizumab intravitreal injection in?
What development phase is ranibizumab intravitreal injection in?
What are the side effects of ranibizumab intravitreal injection?
What does ranibizumab intravitreal injection target?
Related
- Drug class: All anti-VEGF agent drugs
- Target: All drugs targeting VEGF-A
- Manufacturer: Hawaii Pacific Health — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of neovascular (wet) age-related macular degeneration
- Indication: Drugs for Treatment of macular edema following retinal vein occlusion
- Compare: ranibizumab intravitreal injection vs similar drugs
- Pricing: ranibizumab intravitreal injection cost, discount & access